Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma

NCT02662504 | Completed Phase 2 DMC

• 2 other identifiers: 2014_012015-001554-15
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis (median survival \<13 months), and high resistance to chemotherapy. Extended pleurectomy/decortication (eP/D) is a debulking surgery of MPM but cannot be considered as a curative treatment. Therefore it has been suggested that eP/D may be of interest if combined with intra-operative treatment and adjuvant therapies. Photodynamic Therapy (PDT) is an innovative treatment based on the rationale that tumour cells, if previously treated with photosensitizing drugs (Photofrin), will die when exposed to light at a particular wavelength. Interestingly PDT might also stimulate anti-tumour immune response through the release of tumour antigens and induced inflammation. PDT was tested in phase I-II trials for MPM in combination with EPP or eP/D, and chemotherapy. US studies from J Friedberg et al found very promising survival results in MPM when combining eP/D, but not EPP, intra-operative PDT and chemotherapy (cisplatin-pemetrexed), with a median overall survival of 31.7 months. However, the definitive value of intra-pleural PDT combined to eP/D in the treatment of MPM still need to be validated. The same multimodal treatment has been established in Lille, the French national expert centre for MPM, with the help of our american colleagues. Therefore, this phase II trial proposes to patients to benefit from the combination of eP/D, intra-operative PDT then chemotherapy by cisplatin-pemetrexed and prophylactic radiotherapy. Primary endpoint is the feasibility for the patients to have the full multimodal treatment of MPM including intrapleural PDT without unacceptable or unexpected grade III-IV toxicities. Secondary endpoints are PFS, OS, ORR, and quality of life. If the feasibility of such treatment would be confirmed in France, a multicentric, randomized trial comparing this experimental treatment vs control arm (same multimodal treatment without PDT) is planned.

Conditions

Malignant Pleural Mesothelioma

Keywords

mesothelioma; multimodal treatment; PDT; pleura

Outcome Measures

Primary Outcomes (1)

• Number of Patients having the full multimodal treatment without unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0

  at 12 months

Secondary Outcomes (3)

• Number of responders or stable patients after surgery

  at 12 months

• Progression-free survival (PFS)

  through study completion, an average of 13 months

• Quality of life assessed by a specific questionnaire MPM (HCCA EORTC-30)

  Baseline and at 12 months

Study Arms (1)

multimodal treatment + intrapleural PDT

EXPERIMENTAL

* surgery of the MPM: extended pleurectomy/decortication (eP/D) * intra-operative (intrapleural) photodynamic therapy (PDT). Briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks. then: * prophylactic chest radiotherapy of surgical scars to prevent tumor seeding (3 x 7 Gray) * adjuvant standard chemotherapy by (cis)platin 75 mg/m2 and pemetrexed 500 mg/m2 up to 6 cycles (1 cycle every 3 weeks), with oral folic acid (400 μg daily) and vitamin B12 (1000 μg Q9W) supplementation

Device: photodynamic therapy (PDT); Procedure: thoracic surgery Pleurectomy / extended Decortication; Drug: Adjuvant chemotherapy

Interventions

photodynamic therapy (PDT) DEVICE

Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks. After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the "pleural" cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period.

Also known as: Photofrin

multimodal treatment + intrapleural PDT

thoracic surgery Pleurectomy / extended Decortication PROCEDURE

extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected

multimodal treatment + intrapleural PDT

Adjuvant chemotherapy DRUG

Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.

Also known as: pemetrexed / cisplatin

multimodal treatment + intrapleural PDT

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• histologically-proved epithelioid malignant pleural mesothelioma (MPM) on biopsies obtained before eP/D surgery
• tumor stage: no tumor extension to controlateral lung, mediastinum, peritoneum or myocardium (\<T4); mediastinal lymph nodes extension: cN2 but no bulky N2 or N3), no metastasis (M0)
• Performance status WHO PS 0-1
• patients fit to have surgery (eP/D) and chemotherapy (cisplatin-pemetrexed), based on clinical examination, complete normal biological work-up, full assessment by cardiac and pulmonary function tests. Predicted post-surgical values should be sufficient for normal daily life: FEV1\>40%; pre-surgical DLCO\>50% predicted value and VO2max \>15 ml/min/kg; (left ventricular) cardiac function \>50% and no significant pulmonary artery hypertension

You may not qualify if:

• Another histologic subtype than epithelioid MPM at the time of diagnosis
• Bulky N2, N3 and/or M1 stage (UICC/IMIG 1995)
• prior chemotherapy for mesothelioma
• prior radiotherapy of thorax, neck or upper abdomen
• other malignancy treated within 5 years, except basal cell carcinoma or in situ carcinoma of the cervix
• contra-indication for MPM surgery or chemotherapy (cisplatin and pemetrexed): cardiac failure, pulmonary hypertension, liver or kidney dysfunction (GFR\<60 ml/min), uncontrolled infection, previous major neurotoxicity or ototoxicity,... or other severe condition according to the investigator
• pregnancy or breast feeding
• contra-indication for porfimer sodium (Photofrin): porphyria or known hypersensitivity to porphyrins, severe hepatic impairment, tracheo-oesophageal or broncho-oesophageal fistula, suspected erosion of major blood vessels due to risk of massive, potentially fatal haemorrhage

Sponsors & Collaborators

• University Hospital, Lille: lead
• Institut National de la Santé Et de la Recherche Médicale, France: collaborator
• University of Pennsylvania: collaborator
• Région Nord-Pas de Calais, France: collaborator

Study Sites (1)

CHRU de Lille Hôpital Calmette

Lille, France

Location

Related Publications (1)

• Munck C, Mordon S, Betrouni N. Illumination profile characterization of a light device for the dosimetry of intra-pleural photodynamic therapy for mesothelioma. Photodiagnosis Photodyn Ther. 2016 Dec;16:23-26. doi: 10.1016/j.pdpdt.2016.08.010. Epub 2016 Sep 1.

  PMID: 27594672 RESULT

MeSH Terms

Conditions

Mesothelioma, Malignant; Mesothelioma

Interventions

Photochemotherapy; Chemotherapy, Adjuvant; Pemetrexed; Cisplatin

Condition Hierarchy (Ancestors)

Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Mesothelial; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Pleural Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Combined Modality Therapy; Therapeutics; Drug Therapy; Phototherapy; Guanine; Hypoxanthines; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Dicarboxylic; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Study Officials

• Arnaud Scherpereel, MD, PhD

  University Hospital, Lille

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 14, 2016
• First Posted: January 25, 2016
• Study Start: January 16, 2016
• Primary Completion: March 12, 2018
• Study Completion: March 13, 2018
• Last Updated: February 5, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)